The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Tracking changes in circulating stromal cells and circulating tumor cells predicts responsiveness of new line induction in metastatic breast cancer after 1 cycle of therapy.
 
Daniel L Adams
Employment - Creatv MicroTech
Stock and Other Ownership Interests - Creatv MicroTech
Patents, Royalties, Other Intellectual Property - Inventor and co-inventor on multiple US patents
 
R. Katherine Alpaugh
No Relationships to Disclose
 
Rena G. Lapidus
Leadership - KinaRx
 
Saranya Chumsri
Consulting or Advisory Role - AstraZeneca/Daiichi Sankyo; Athenex; Athenex; bioTheranostics; bioTheranostics (Inst); Eisai; Immunomedics; Immunomedics; Immunomedics; Novartis; Novartis; Puma Biotechnology; Syndax
Research Funding - Array BioPharma; Merck
 
Carolina Reduzzi
Research Funding - Menarini Silicon Biosystems
 
Cha-Mei Tang
Employment - Creatv MicroTech
Leadership - Creatv MicroTech
Stock and Other Ownership Interests - Creatv MicroTech
Patents, Royalties, Other Intellectual Property - Creatv MicroTech
 
William Williams
Employment - Briacell
Leadership - Briacell
Stock and Other Ownership Interests - Briacell
Consulting or Advisory Role - Briacell
Research Funding - Briacell
Patents, Royalties, Other Intellectual Property - Briacell
Travel, Accommodations, Expenses - Briacell
 
Massimo Cristofanilli
Honoraria - Foundation Medicine; Pfizer
Consulting or Advisory Role - AstraZeneca/Daiichi Sankyo; Ellipses Pharma; Foundation Medicine; Lilly; Menarini; Olaris
Research Funding - Angle; Lilly; Merck